Drugmaker AbbVie on Friday said it has agreed in principle to pay more than $2 billion to settle thousands of lawsuits related to the marketing of opioids by Allergan, a former opioid manufacturer that has since been bought by AbbVie.
The complete terms of the settlement have not yet been finalized, and a bipartisan group of state attorneys general said precise state allocations have yet to be announced.
The company did not respond to a request for comment, but disclosed the settlement in its quarterly earnings report on Friday.
If finalized, the Allergan settlement, together with the Teva Pharmaceuticals settlement announced earlier this week, would provide as much as $6.6 billion nationwide.
